Peptide questions · Semaglutide
Semaglutide side effects: what studies and users report
Reviewed Evidence: EstablishedPublished by PepVault
The side effects most commonly reported for semaglutide are nausea, vomiting and diarrhea, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: Across the STEP and SELECT programs, semaglutide's adverse events are predominantly mild-to-moderate transient gastrointestinal effects; in SELECT, discontinuation for adverse events was higher than placebo (16.6% vs 8.2%), driven by GI events, while overall serious adverse events were actually lower than placebo.
What is commonly reported with semaglutide
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
- Fatigue
- Pancreatitis risk
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide (oral), Tirzepatide, Retatrutide, Liraglutide and 17 more |
| Vomiting | 18: Semaglutide (oral), Tirzepatide, Retatrutide, Liraglutide and 14 more |
| Diarrhea | 20: Semaglutide (oral), Tirzepatide, Retatrutide, Liraglutide and 16 more |
| Constipation | 13: Semaglutide (oral), Tirzepatide, Retatrutide, Liraglutide and 9 more |
| Decreased appetite | 9: Semaglutide (oral), Tirzepatide, Retatrutide, Dulaglutide and 5 more |
| Fatigue | 7: Tirzepatide, Retatrutide, Dulaglutide, Survodutide and 3 more |
| Pancreatitis risk | 1: Liraglutide |

Model. Individual results vary.
Which semaglutide side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Every effect on semaglutide’s list also appears for at least one other metabolic & GLP-1 compound, so nothing on it is semaglutide’s own.
What the semaglutide safety notes say
The library’s safety note
Across the STEP and SELECT programs, semaglutide's adverse events are predominantly mild-to-moderate transient gastrointestinal effects; in SELECT, discontinuation for adverse events was higher than placebo (16.6% vs 8.2%), driven by GI events, while overall serious adverse events were actually lower than placebo. Gallbladder-related events were more frequent than placebo (2.8% vs 2.3% in SELECT, mostly gallstones), and acute pancreatitis was rare with no notable signal vs placebo across STEP 1-5. It shares the GLP-1-class rodent thyroid C-cell warning. These are trial/label findings — discuss with your clinician.
The library’s interaction note
Like the GLP-1 class, semaglutide delays gastric emptying and can affect absorption of oral medications — a label-level consideration; discuss oral-drug timing with your clinician. Combined with insulin or sulfonylureas, additive glucose-lowering increases hypoglycemia risk per the label, warranting clinician-guided monitoring. No specific documented interaction with SSRIs or anticoagulants beyond general caution; raise all medications and supplements with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the semaglutide reports come from
The library rates the evidence on semaglutide as established: clinical trials or FDA-approved use exist.
Of the library’s 11 research notes on semaglutide, 9 rest on randomized trials, 1 on clinical data and 1 on community reports.
Our 31 study pages on semaglutide: 29 randomized trials, 1 animal study (mice) and 1 meta-analysis.
So semaglutide has controlled trials in people to set its listed effects against.
What our semaglutide study pages report on safety
Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3
Randomized trial, human, 2026: Stomach and gut side effects, mostly mild to moderate, hit 37% and 45% of the semaglutide arms versus 59% and 58% of the orforglipron arms. Fewer people quit semaglutide because of side effects (4% and 5%, versus 9% and 10%), and pulse rose less on semaglutide (1.0 and 1.5 bpm, versus 3.7 and 4.7 bpm).
Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetes
Randomized trial, human, 2025: This was a small, 26-week trial, so it can't show longer-term effects or rarer side effects.
Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4
Randomized trial, human, 2025: Stomach and gut side effects were more common on the pill than on placebo (74.0% vs. 42.2%). A daily 25 mg semaglutide pill led to clearly more weight loss than placebo over 64 weeks, with stomach and gut side effects in 74.0% of users.
Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeks
Randomized trial, human, 2025: Bodily pain scores did not differ significantly between groups, and gut-related side effects were more common with semaglutide. In a large placebo-controlled trial, weekly semaglutide improved liver biopsy results in people with MASH and moderate or advanced scarring, with more gut side effects than placebo.
Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UP
Randomized trial, human, 2025: Gut side effects hit 70.8% on 7.2 mg, 61.2% on 2.4 mg and 42.8% on placebo, and dysesthesia (odd or unpleasant skin sensations) hit 22.9%, 6.0% and 0.5%. Serious adverse events occurred in 6.8%, 10.9% and 5.5%, and the authors judged the 7.2 mg dose's risk-benefit balance favorable.
Semaglutide: 24% lower risk of major kidney events in FLOW
Randomized trial, human, 2024: Death from heart and blood vessel causes was also lower (hazard ratio 0.71), as were major cardiovascular events (hazard ratio 0.82) and death from any cause (hazard ratio 0.80). eGFR fell more slowly each year with semaglutide, by 1.16 ml per minute per 1.73 m2, and serious side effects were reported in 49.6% of the semaglutide group versus 53.8% of the placebo group. For people with type 2 diabetes and chronic kidney disease, this large trial links semaglutide to fewer serious kidney events and fewer deaths from heart causes than placebo over a median of 3.4 years.
Questions people ask
What are the side effects of semaglutide?
The side effects most commonly reported for semaglutide are nausea, vomiting and diarrhea, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Do semaglutide’s side effects come from human studies?
The library rates the evidence on semaglutide as established, and the library’s evidence on it includes controlled trials in people.
Which semaglutide side effects are its own?
None: each effect the library lists for semaglutide is listed for at least one other metabolic & GLP-1 compound too.
Does semaglutide interact with other medicines?
The library’s interaction note on semaglutide begins: Like the GLP-1 class, semaglutide delays gastric emptying and can affect absorption of oral medications — a label-level consideration; discuss oral-drug timing with your clinician.